PSMA Radioligand Therapy | Advances in Prostate Cancer Treatments | Part 2

By Applied Radiology

Response rates to Lutetium PSMA treatments are good, however they are not a cure for Prostate Cancer.  What’s next for these patients may include Alpha therapies attached to antibodies, which are quite effective and have longer efficacy when compared to other developing therapies. Nat Lenzo, MD explains the potential benefits of Alpha antibody therapy.  Hear more.  

Supported by Telix Pharmaceuticals as a service to medicine - Telix respects the independence of healthcare professionals and the views are those of the presenter.

Back To Top

PSMA Radioligand Therapy | Advances in Prostate Cancer Treatments | Part 2.  Appl Radiol. 

March 24, 2022



Copyright © Anderson Publishing 2022